Newron Pharmaceuticals S.p.A.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Newron Pharmaceuticals S.p.A.
A new decision from the PTAB upholds prior rulings rejecting four of Masimo’s appeals and reverses a decision on one.
Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a recent analysis of FDA approval decisions since 2021.
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
- Other Names / Subsidiaries
- NeuroNova AB
- Newron Pharmaceuticals SpA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.